DEBRA CORRIGAN: Open Payments
NPI 1043582273 · ROCKFORD, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,177 in 103 payments from 16 companies in 2025. Trend: 2023 $2,767 · 2024 $2,610 · 2025 $2,177
Food & beverage: $2,177
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 13 | $289 |
| Supernus Pharmaceuticals, Inc. | 8 | $264 |
| ABBVIE INC. | 15 | $255 |
| Lundbeck LLC | 9 | $180 |
| Janssen Pharmaceuticals, Inc | 6 | $160 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $158 |
| Otsuka America Pharmaceutical, Inc. | 6 | $150 |
| Teva Pharmaceuticals USA, Inc. | 7 | $149 |
| E.R. Squibb & Sons, L.L.C. | 10 | $145 |
| Axsome Therapeutics, Inc. | 7 | $131 |
Products named: INGREZZA, Qelbree, VRAYLAR, REXULTI, SPRAVATO, CAPLYTA, COBENFY, AUSTEDO XR.
Industry payments across IL — which companies pay providers there.
